View More View Less
  • 1 Szent Ferenc Kórház Reumatológiai Osztály Miskolc
  • | 2 Debreceni Egyetem, Orvos- és Egészségtudományi Centrum Belgyógyászati Intézet, III. sz. Belgyógyászati Klinika, Reumatológiai Tanszék Debrecen Móricz Zs. krt. 22. 4004
Restricted access

A biológiai terápia lényege, hogy a gyulladás egyetlen, jól meghatározott pontján (pl. egy adott citokin szintjén) hat. Ezáltal a sokszor igen bonyolult mechanizmusokból álló patogenetikai hálózatot egy adott ponton szakítja meg. Ma a rheumatoid arthritis a biológiai terápia szempontjából modellbetegség, mivel a legtöbb szerrel ebben a kórképben próbálkoztak. Ezt követően egyéb arthritisekben (pl. spondylitis ankylopoetica, psoriasisos arthropathia), majd egyes szisztémás autoimmun kórképekben (pl. szisztémás lupus erythematosus, scleroderma, myositisek, vasculitisek, Sjögren-szindróma stb.) kezdték el alkalmazni. A legtöbb kórkép esetében egy központi szereppel bíró citokin, a tumornekrózis faktor-α (TNF-α) gátlószerei állnak a terápia középpontjában. Azonban a biológiai terápia megtervezésekor az adott kórkép patogenezisét (pl. döntően Th1 vagy Th2 jellegét) figyelembe kell venni. Nem véletlen, hogy amíg egyes kórképekben (pl. rheumatoid arthritis, spondylitis ankylopoetica, psoriasis, polymyositis, polyarticularis juvenilis arthritis) döntően a TNF-blokkolók és a T-sejtek elleni gátlás vált be, addig másoknál (pl. lupus, Sjögren-szindróma, dermatomyositis) a B-sejt elleni terápia kecsegtet sikerrel. Ezen összefoglalóban a szerzők áttekintik az arthritisek és szisztémás autoimmun kórképek biológiai terápiájára vonatkozó legfontosabb adatokat. Kitérnek az alkalmazott szerek tulajdonságaira, a hatékonyság és biztonságosság kérdéseire egyaránt.

  • Anandarajah, A., Ritchlin, C. T.: Treatment update on spondyloarthropathy. Curr. Opin. Rheumatol., 2005, 17 , 247–256.

    Ritchlin C. T. , 'Treatment update on spondyloarthropathy ' (2005 ) 17 Curr. Opin. Rheumatol. : 247 -256.

    • Search Google Scholar
  • Anolik, J. H., Aringer, M.: New treatments of SLE: cell-depleting and anti-cytokine therapies. Best Parct. Res. Clin. Rheumatol., 2005, 19 , 859–878.

    Aringer M. , 'New treatments of SLE: cell-depleting and anti-cytokine therapies ' (2005 ) 19 Best Parct. Res. Clin. Rheumatol. : 859 -878.

    • Search Google Scholar
  • Antoni, C. E., Kavanaugh, A., Kirkham, B. és mtsai: Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum., 2005, 52 , 1227–1236.

    Kirkham B. , 'Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT) ' (2005 ) 52 Arthritis Rheum. : 1227 -1236.

    • Search Google Scholar
  • Aringer, M., Graninger, W. B., Steiner, G. és mtsai: Safety and efficacy of tumor necrosis alpha blockade in systemic lupus erythematosus: an open-label study. Arthritis Rheum., 2004, 50 , 3161–3169.

    Steiner G. , 'Safety and efficacy of tumor necrosis alpha blockade in systemic lupus erythematosus: an open-label study ' (2004 ) 50 Arthritis Rheum. : 3161 -3169.

    • Search Google Scholar
  • Brandt, J., Braun, J.: Anti-TNF agents in the treatment of psoriatic arthritis. Expert Opin. Biol. Ther., 2006, 6 , 99–107.

    Braun J. , 'Anti-TNF agents in the treatment of psoriatic arthritis ' (2006 ) 6 Expert Opin. Biol. Ther. : 99 -107.

    • Search Google Scholar
  • Braun, J., Baraliakos, X., Golder, W. és mtsai: Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of new scoring system. Arthritis Rheum., 2003, 48 , 1126–1136.

    Golder W. , 'Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of new scoring system ' (2003 ) 48 Arthritis Rheum. : 1126 -1136.

    • Search Google Scholar
  • Braun, J., Baraliakos, X., Listing, J. és mtsai: Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum., 2005, 52 , 2447–2451.

    Listing J. , 'Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept ' (2005 ) 52 Arthritis Rheum. : 2447 -2451.

    • Search Google Scholar
  • Breedveld, F. C., Weisman, M. H., Kavanaugh, A. F. és mtsai: The PREMIER study a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate alone or adalimumab alone in patients with early aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum., 2006, 54 , 26–37.

    Kavanaugh A. F. , 'The PREMIER study a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate alone or adalimumab alone in patients with early aggressive rheumatoid arthritis who had not had previous methotrexate treatment ' (2006 ) 54 Arthritis Rheum. : 26 -37.

    • Search Google Scholar
  • Burns, J. C., Mason, W. H., Hauger, S. B. és mtsai: Infliximab treatment for refractory Kawasaki syndrome. J. Pediatr., 2005, 146 , 662–667.

    Hauger S. B. , 'Infliximab treatment for refractory Kawasaki syndrome ' (2005 ) 146 J. Pediatr. : 662 -667.

    • Search Google Scholar
  • Calin, A., Dijkmans, B. A. C., Emery, P. és mtsai: Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann. Rheum. Dis., 2004, 63 , 1594–1600.

    Emery P. , 'Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis ' (2004 ) 63 Ann. Rheum. Dis. : 1594 -1600.

    • Search Google Scholar
  • Carrasco, R., Smith, J. A., Lovell, D.: Biologic agents for the treatment of juvenile rheumatoid arthritis: current status. Paediatr. Drugs., 2004, 6 , 137–146.

    Lovell D. , 'Biologic agents for the treatment of juvenile rheumatoid arthritis: current status ' (2004 ) 6 Paediatr. Drugs. : 137 -146.

    • Search Google Scholar
  • Christopher-Stine, L., Wigley, F.: Tumor necrosis factor-alpha antagonists induce lupus-like syndrome in patients with scleroderma overlap/mixed connective tissue disease. J. Rheumatol., 2003, 30 , 2725–2727.

    Wigley F. , 'Tumor necrosis factor-alpha antagonists induce lupus-like syndrome in patients with scleroderma overlap/mixed connective tissue disease ' (2003 ) 30 J. Rheumatol. : 2725 -2727.

    • Search Google Scholar
  • Denton, C. P., Black, C. M.: Targeted therapy comes of age in scleroderma. Trends Immunol., 2005, 26 , 596–602.

    Black C. M. , 'Targeted therapy comes of age in scleroderma ' (2005 ) 26 Trends Immunol. : 596 -602.

    • Search Google Scholar
  • Edwards, J. C. W., Szczepanski, L., Szechinski, J. és mtsai: Efficacy of B-cell targeted therapy with rituximab in patients with rheumatoid arthritis. N. Engl. J. Med., 2004, 350 , 2572–2581.

    Szechinski J. , 'Efficacy of B-cell targeted therapy with rituximab in patients with rheumatoid arthritis ' (2004 ) 350 N. Engl. J. Med. : 2572 -2581.

    • Search Google Scholar
  • Efthimiou, P., Schwartzman, S., Kagen, L.: Possible role for TNF inhibitors in the treatment of resistant dermatomyositis and polymyositis. Ann. Rheum. Dis., 2006 Feb (e-pub ahead of print).

  • Furst, D. E., Breedveld, F. C., Kalden, J. R. és mtsai: Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNF) blocking agents and interleukin-1 receptor antagonist (IL-1ra) for the treatment of rheumatic diseases 2005. Ann. Rheum. Dis., 2005, 64 , iv2-iv14.

    Kalden J. R. , 'Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNF) blocking agents and interleukin-1 receptor antagonist (IL-1ra) for the treatment of rheumatic diseases 2005 ' (2005 ) 64 Ann. Rheum. Dis. : iv2 -iv14.

    • Search Google Scholar
  • Geborek, P., Bladstrom, A., Turesson, C. és mtsai: Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann. Rheum. Dis., 2005, 64 , 699–703.

    Turesson C. , 'Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas ' (2005 ) 64 Ann. Rheum. Dis. : 699 -703.

    • Search Google Scholar
  • Gerloni, V., Pontikaki, I., Gattinara, M. és mtsai: Efficacy of repeated intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody, infliximab, in persistently active, refractory juvenile idiopathic arthritis. Arthritis Rheum., 2005, 52 , 548–553.

    Gattinara M. , 'Efficacy of repeated intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody, infliximab, in persistently active, refractory juvenile idiopathic arthritis ' (2005 ) 52 Arthritis Rheum. : 548 -553.

    • Search Google Scholar
  • Gottlieb, A. B.: Alefacept for psoriasis and psoriatic arthritis. Ann. Rheum. Dis., 2005, 64 (Suppl 4) , iv58–60.

    Gottlieb A. B. , 'Alefacept for psoriasis and psoriatic arthritis ' (2005 ) 64 Ann. Rheum. Dis. : iv58 -60.

    • Search Google Scholar
  • Gottlieb, A. B., Hamilton, T., Caro, I. és mtsai: Long-term continuous efalizumab therapy in patients with moderate to severe chronic plaque psoriasis. J. Am. Acad. Dermatol., 2006, 54 , S154–S163.

    Caro I. , 'Long-term continuous efalizumab therapy in patients with moderate to severe chronic plaque psoriasis ' (2006 ) 54 J. Am. Acad. Dermatol. : S154 -S163.

    • Search Google Scholar
  • Haibel, H., Rudwaleit, M., Brandt, H. C. és mtsai: Adalimumab reduces spinal symptoms in active ankylosing spondylitis: clinical and magnetic resonance imaging results of a fifty-two week open-label trial. Arthritis Rheum., 2006, 54 , 678–681.

    Brandt H. C. , 'Adalimumab reduces spinal symptoms in active ankylosing spondylitis: clinical and magnetic resonance imaging results of a fifty-two week open-label trial ' (2006 ) 54 Arthritis Rheum. : 678 -681.

    • Search Google Scholar
  • Hansen, A., Lipsky, P. E., Dörner, T.: Immunopathogenesis of primary Sjögren’s syndrome: implications for disease management and therapy. Curr. Opin. Rheumatol., 2005, 17 , 558–565.

    Dörner T. , 'Immunopathogenesis of primary Sjögren’s syndrome: implications for disease management and therapy ' (2005 ) 17 Curr. Opin. Rheumatol. : 558 -565.

    • Search Google Scholar
  • Kalden, J. R.: Emerging role of anti-tumor necrosis factor therapy in rheumatic diseases. Arthritis Res., 2002, Suppl 2 , S34–S40.

    Kalden J. R. , 'Emerging role of anti-tumor necrosis factor therapy in rheumatic diseases ' (2002 ) Suppl 2 Arthritis Res. : S34 -S40.

    • Search Google Scholar
  • Klareskog, L., van der Heijde, D., de Jager, J. P. és mtsai: Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet, 2004, 28 , 675–681.

    Jager J. P. , 'Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial ' (2004 ) 28 Lancet : 675 -681.

    • Search Google Scholar
  • Kremer, J. M.: Selective costimulation modulators: a novel approach for the treatment of rheumatoid arthritis. J. Clin. Rheumatol., 2005, Suppl 11 , S55–S62.

    Kremer J. M. , 'Selective costimulation modulators: a novel approach for the treatment of rheumatoid arthritis ' (2005 ) Suppl 11 J. Clin. Rheumatol. : S55 -S62.

    • Search Google Scholar
  • Lamprecht, P.: TNF-alpha inhibitors in systemic vasculitides and connective tissue diseases. Autoimmun Rev., 2005, 4 , 28–34.

    Lamprecht P. , 'TNF-alpha inhibitors in systemic vasculitides and connective tissue diseases ' (2005 ) 4 Autoimmun Rev. : 28 -34.

    • Search Google Scholar
  • Levine, T. D.: Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum., 2005, 52 , 601–607.

    Levine T. D. , 'Rituximab in the treatment of dermatomyositis: an open-label pilot study ' (2005 ) 52 Arthritis Rheum. : 601 -607.

    • Search Google Scholar
  • Lovell, D. J., Giannini, E. H., Reiff, A. és mtsai: Long-term efficacy and safety of etanercept in children with polyarticular course juvenile rheumatoid arthritis. Arthritis Rheum., 2003, 48 , 218–226.

    Reiff A. , 'Long-term efficacy and safety of etanercept in children with polyarticular course juvenile rheumatoid arthritis ' (2003 ) 48 Arthritis Rheum. : 218 -226.

    • Search Google Scholar
  • Maini, R. N., Breedveld, F. C., Kalden, J. és mtsai: Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum., 1998, 41 , 1552–1563.

    Kalden J. , 'Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis ' (1998 ) 41 Arthritis Rheum. : 1552 -1563.

    • Search Google Scholar
  • Mease, P. J., Kivitz, A. J., Burch, F. X. és mtsai: Etanercept treatment of psoriatic arthritis, safety, efficacy and effect on disease progression. Arthritis Rheum., 2004, 50 , 2264–2272.

    Burch F. X. , 'Etanercept treatment of psoriatic arthritis, safety, efficacy and effect on disease progression ' (2004 ) 50 Arthritis Rheum. : 2264 -2272.

    • Search Google Scholar
  • Mease, P. J., Gladman, D. D., Ritchlin, C. T. és mtsai: Adalimumab for the treatment of patients with moderately to severe active psoriatic arthritis: results of double-blind, randomized, placebo-controlled trial. Arthritis Rheum., 2005, 52 , 3279–3289.

    Ritchlin C. T. , 'Adalimumab for the treatment of patients with moderately to severe active psoriatic arthritis: results of double-blind, randomized, placebo-controlled trial ' (2005 ) 52 Arthritis Rheum. : 3279 -3289.

    • Search Google Scholar
  • Nuki, G., Bresnihan, B., Bear, M. B. és mtsai: Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis. Arthritis Rheum., 2002, 46 , 2838–2846.

    Bear M. B. , 'Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis ' (2002 ) 46 Arthritis Rheum. : 2838 -2846.

    • Search Google Scholar
  • Pijpe, J., van Imhoff, G. W., Spijkervet, F. K. és mtsai: Rituximab treatment in patients with primary Sjögren’s syndrome. Arthritis Rheum., 2005, 52 , 2740–2750.

    Spijkervet F. K. , 'Rituximab treatment in patients with primary Sjögren’s syndrome ' (2005 ) 52 Arthritis Rheum. : 2740 -2750.

    • Search Google Scholar
  • Pollard, L., Choy, E.: Rheumatoid arthritis: non-tumor necrosis factor targets. Curr. Opin. Rheumatol., 2005, 17 , 242–246.

    Choy E. , 'Rheumatoid arthritis: non-tumor necrosis factor targets ' (2005 ) 17 Curr. Opin. Rheumatol. : 242 -246.

    • Search Google Scholar
  • Ramos-Casals, M., Tzioufas, A. G., Font, J.: Primary Sjögren’s syndrome: new clinical and therapeutic concepts. Ann. Rheum. Dis., 2005, 64 , 347–354.

    Font J. , 'Primary Sjögren’s syndrome: new clinical and therapeutic concepts ' (2005 ) 64 Ann. Rheum. Dis. : 347 -354.

    • Search Google Scholar
  • Ratanatharathorn, V., Ayash, L., Reynolds, C. és mtsai: Treatment of chronic graft-versus-host disease with anti-CD20 chimeric monoclonal antibody. Biol. Blood Marrow Transplant., 2003, 9 , 505–511.

    Reynolds C. , 'Treatment of chronic graft-versus-host disease with anti-CD20 chimeric monoclonal antibody ' (2003 ) 9 Biol. Blood Marrow Transplant. : 505 -511.

    • Search Google Scholar
  • Reumatológiai és Fizioterápiás Szakmai Kollégium: Módszertani levél a biológiai terápiák gyulladásos reumatológiai betegségekben történő alkalmazásáról. Magyar Reumatol., 2005, 46 , 199–255.

    'Módszertani levél a biológiai terápiák gyulladásos reumatológiai betegségekben történő alkalmazásáról ' (2005 ) 46 Magyar Reumatol. : 199 -255.

    • Search Google Scholar
  • Ritchlin, C., Haas-Smith, S. A., Hicks, D. és mtsai: Patterns of cytokine production in psoriatic synovium. J. Rheumatol., 1998, 25 , 1544–1552.

    Hicks D. , 'Patterns of cytokine production in psoriatic synovium ' (1998 ) 25 J. Rheumatol. : 1544 -1552.

    • Search Google Scholar
  • Russo, R. A., Katsicas, M. M., Zelazko, M.: Etanercept in systemic juvenile idiopathic arthritis. Clin. Exp. Rheumatol., 2002, 20 , 723–726.

    Zelazko M. , 'Etanercept in systemic juvenile idiopathic arthritis ' (2002 ) 20 Clin. Exp. Rheumatol. : 723 -726.

    • Search Google Scholar
  • Schmeling, H., Horneff, G.: Etanercept and uveitis in patients with juvenile idiopathic arthritis. Rheumatology, 2005, 44 , 1008–1011.

    Horneff G. , 'Etanercept and uveitis in patients with juvenile idiopathic arthritis ' (2005 ) 44 Rheumatology : 1008 -1011.

    • Search Google Scholar
  • Sfikakis, P. P., Boletis, J. N., Tsokos, G. C.: Rituximab anti-B-cell therapy in systemic lupus erythematosus: pointing to the future. Curr. Opin. Rheumatol., 2005, 17 , 550–557.

    Tsokos G. C. , 'Rituximab anti-B-cell therapy in systemic lupus erythematosus: pointing to the future ' (2005 ) 17 Curr. Opin. Rheumatol. : 550 -557.

    • Search Google Scholar
  • St. Clair, E. W., van der Heijde, D. M., Smolen, J. S. és mtsai: Combination of infliximab and methotreaxate therapy for early rheumatoid arthritis: a randomized controlled trial. Arthritis Rheum., 2004, 50 , 3432–3443.

    Smolen J. S. , 'Combination of infliximab and methotreaxate therapy for early rheumatoid arthritis: a randomized controlled trial ' (2004 ) 50 Arthritis Rheum. : 3432 -3443.

    • Search Google Scholar
  • Strand, C. V., Keystone, E.: Biologic agents for the treatment of rheumatoid arthritis. In Kelley’s Textbook of Rheumatology, 6th ed., WB Saunders, 2001, Philadelphia. 899–912.

    Keystone E. , '', in Kelley’s Textbook of Rheumatology , (2001 ) -.

  • Swale, V. J., Perrett, C. M., Denton, C. P. és mtsai: Etanercept-induced systemic lupus erythematosus. Clin. Exp. Dermatol., 2003, 28 , 604–607.

    Denton C. P. , 'Etanercept-induced systemic lupus erythematosus ' (2003 ) 28 Clin. Exp. Dermatol. : 604 -607.

    • Search Google Scholar
  • Szegedi Gy.: Immunmoduláció az autoimmun betegségek terápiájában. Új remények az autoimmun betegségben szenvedők számára. Orv. Hetil., 2005, 14 , 635–643.

    Szegedi Gy. , 'Immunmoduláció az autoimmun betegségek terápiájában. Új remények az autoimmun betegségben szenvedők számára ' (2005 ) 14 Orv. Hetil. : 635 -643.

    • Search Google Scholar
  • Szekanecz Z., Gömör B.: Az antireumatikus terápia újabb lehetőségei a XXI. században. MOTESZ Magazin, 2001, 1–2 , 23–31.

    Gömör B. , 'Az antireumatikus terápia újabb lehetőségei a XXI. században ' (2001 ) 1–2 MOTESZ Magazin : 23 -31.

    • Search Google Scholar
  • Szekanecz Z., Balogh Zs., Géher P. és mtsai: Az ízületi gyulladások korszerű diagnosztikája és terápiája. Orvostovábbképző Szemle, 2005, Suppl , 11–17.

    Géher P. , 'Az ízületi gyulladások korszerű diagnosztikája és terápiája ' (2005 ) Suppl Orvostovábbképző Szemle : 11 -17.

    • Search Google Scholar
  • Thatayatikom, A., White, A. J.: Rituximab: a promising therapy in systemic lupus erythematosus. Autoimmun Rev., 2006, 5 , 18–24.

    White A. J. , 'Rituximab: a promising therapy in systemic lupus erythematosus ' (2006 ) 5 Autoimmun Rev. : 18 -24.

    • Search Google Scholar
  • Thomas, R., Lipsky, P. E.: Presentation of self peptides by dentritic cells: possible implications for the pathogenesis of rheumatoid arthritis. Arthritis Rheum., 1996, 39 , 183–190.

    Lipsky P. E. , 'Presentation of self peptides by dentritic cells: possible implications for the pathogenesis of rheumatoid arthritis ' (1996 ) 39 Arthritis Rheum. : 183 -190.

    • Search Google Scholar
  • Tutuncu, Z., Morgan, G. J. jr., Kavanaugh, A.: Anti-TNF therapy for other inflammatory conditions. Clin. Exp. Rheumatol., 2002, Suppl 28 , S146–S151.

    Kavanaugh A. , 'Anti-TNF therapy for other inflammatory conditions ' (2002 ) Suppl 28 Clin. Exp. Rheumatol. : S146 -S151.

    • Search Google Scholar
  • Tynjala, P., Lahdenne, P., Vahasalo, P. és mtsai: Impact of anti-TNF therapy on growth in severe juvenile idiopathic arthritis. Ann. Rheum. Dis., 2006. január (e-pub ahead of print).

  • Weinberg, J. M., Bottino, C. J., Lindholm, J. és mtsai: Biologic therapy for psoriasis: an update on the tumor necrosis factor inhibitors infliximab, etanercept and adalimumab, and the T-cell-targeted therapies efalizumab and alefacept. J. Drugs Dermatol., 2005, 4 , 544–555.

    Lindholm J. , 'Biologic therapy for psoriasis: an update on the tumor necrosis factor inhibitors infliximab, etanercept and adalimumab, and the T-cell-targeted therapies efalizumab and alefacept ' (2005 ) 4 J. Drugs Dermatol. : 544 -555.

    • Search Google Scholar
  • Weinblatt, M. E., Keystone, E. C., Furst, D. E. és mtsai: Adalimumab, a fully human anti- tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomittant methotrexate: the ARMADA trial. Arthritis Rheum., 2003, 48 , 35–45.

    Furst D. E. , 'Adalimumab, a fully human anti-tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomittant methotrexate: the ARMADA trial ' (2003 ) 48 Arthritis Rheum. : 35 -45.

    • Search Google Scholar
  • Winterfield, L. S., Menter, A., Gordon, K. és mtsai: Psoriasis treatment: current and emerging directed therapies. Ann. Rheum. Dis., 2005, 64 Suppl 2 , ii87–90.

    Gordon K. , 'Psoriasis treatment: current and emerging directed therapies ' (2005 ) 64 Ann. Rheum. Dis. : ii87 -90.

    • Search Google Scholar

Monthly Content Usage

Abstract Views Full Text Views PDF Downloads
Jan 2021 15 0 0
Feb 2021 39 1 2
Mar 2021 25 1 1
Apr 2021 26 3 1
May 2021 20 0 0
Jun 2021 29 0 0
Jul 2021 0 0 0